Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology

Hepatocellular Carcinoma Clinical Trial

Official title:

A Prospective Randomized Trial on the Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02727673
• Other study ID #: ZD201200102-P1
• Status: Completed
• Phase: N/A
• First received: March 30, 2016
• Last updated: March 30, 2016
• Start date: December 2012
• Est. completion date: December 2014

Study information

• Verified date: March 2016
• Source: Eastern Hepatobiliary Surgery Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The aim of this study is to establish a platform of detecting and sorting circulating tumor stem cells from peripheral blood in HCC patients; to investigate the relationship between circulating tumor stem cells and their effects on postoperative recurrence and metastasis, in order to provide a new therapeutic target for hepatocellular carcinoma treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: December 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male or female patients > 18 years and <=70 years of age;

2. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal.

3. Patients who can understand this trial and have signed information consent

Exclusion Criteria:

1. Reject to attend;

2. Impossible to come to our hospital for physical examination regularly;

3. Patients with other diseases which may affect the treatment mentioned

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cancer Stem Cells
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Postoperative Recurrence and Metastasis
• Recurrence

Locations

Country	Name	City	State
China	Eastern hepatobilliary surgery hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Eastern Hepatobiliary Surgery Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the overall survival rate of each group		3 years	Yes